![Ivan Bergstein](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ivan Bergstein
Amministratore Delegato presso STEMLINE THERAPEUTICS, INC.
Posizioni attive di Ivan Bergstein
Società | Posizione | Inizio | Fine |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Amministratore Delegato | - | - |
Fondatore | 08/08/2003 | - | |
Presidente | 08/08/2003 | - | |
Direttore/Membro del Consiglio | - | - | |
Presidente | 08/08/2003 | 10/06/2020 | |
Segretario Aziendale | 08/08/2003 | 18/02/2014 | |
Treasurer | 08/08/2003 | 18/02/2014 | |
Trading-Fixed Income | 08/08/2003 | 08/08/2003 | |
Lirum Therapeutics, Inc.
![]() Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Presidente | 01/11/2021 | - |
Storia della carriera di Ivan Bergstein
Precedenti posizioni note di Ivan Bergstein
Società | Posizione | Inizio | Fine |
---|---|---|---|
Nitron Advisors
![]() Nitron Advisors Investment ManagersFinance Nitron Advisors operates an investment research company. The private company is based in Saratoga, CA. | Corporate Officer/Principal | - | - |
KERYX BIOPHARMACEUTICALS | Direttore Tecnico/Scientifico/R&S | - | - |
ACCESS Oncology, Inc.
![]() ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Part of Akebia Therapeutics, Inc., ACCESS Oncology, Inc. is a company that develops pharmaceutical drugs. The company is based in New York, NY. The company was founded by Michael Sean Weiss. ACCESS Oncology was acquired by Keryx Biopharmaceuticals, Inc., part of Akebia Therapeutics, Inc. from December 13, 2018 on February 06, 2004 for $36.44 million. | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di Ivan Bergstein
University of Pennsylvania | Undergraduate Degree |
Icahn School of Medicine at Mount Sinai | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Posizioni
Chairman | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Director/Board Member | 1 |
Settori
Health Technology | 5 |
Consumer Services | 3 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 5 |
---|---|
Keryx Biopharmaceuticals, Inc.
![]() Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
ACCESS Oncology, Inc.
![]() ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Part of Akebia Therapeutics, Inc., ACCESS Oncology, Inc. is a company that develops pharmaceutical drugs. The company is based in New York, NY. The company was founded by Michael Sean Weiss. ACCESS Oncology was acquired by Keryx Biopharmaceuticals, Inc., part of Akebia Therapeutics, Inc. from December 13, 2018 on February 06, 2004 for $36.44 million. | Health Technology |
Stemline Therapeutics, Inc.
![]() Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Nitron Advisors
![]() Nitron Advisors Investment ManagersFinance Nitron Advisors operates an investment research company. The private company is based in Saratoga, CA. | Finance |
Lirum Therapeutics, Inc.
![]() Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Ivan Bergstein
- Esperienza